Androgenetic Alopecia Treatment
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Millions of people globally experience some form of hair loss, which typically increases with age. Pattern baldness, also known as androgenic alopecia (AGA), is the leading type, affecting more than half of men over 50 and a significant portion…
Commissions we earn from partner links on this page do not affect our opinions or evaluations. Millions of individuals worldwide are estimated to suffer from androgenetic alopecia, which becomes increasingly common with age. Among popular DHT-blocking treatments, topical dutasteride is considered the most potent, providing dual enzyme inhibition for superior effectiveness compared to finasteride. The…
Commissions we earn from partner links on this page do not affect our opinions or evaluations. This isn’t news about future treatments. Instead, this is about a new U.S.-based telehealth brand, Ulo, and its innovative prescription and over-the-counter treatments for hair growth. There are dozens of telehealth hair care brands, yet Follicle Thought has never…
More news is coming out of Kintor Pharma this month. Kintor Pharma (HKEX: 9939) has announced that its observational study evaluating the combination of KX-826 and minoxidil for the treatment of androgenetic alopecia (AGA) in adult males in China has successfully reached its primary endpoint. This marks another milestone in the development of KX-826, following…
After a slow and disappointing winter season in 2024, we start the year with some positive news in the androgenic alopecia space. Eirion Therapeutics, a clinical-stage biopharmaceutical company with oral and topical androgenic alopecia treatments in the pipeline, has announced results from their 4-week androgenic alopecia trial of topical ET-02. What Is ET-02? We don’t…
Kintor Pharmaceutical has recently announced the enrollment of its first participant in its “Pivotal Clinical Trial”. This is a Phase 2/3 trial in which men with androgenic alopecia will be treated with either vehicle control, 0.5%, or 1% topical for 24 weeks. The trial will be conducted in China, with 222 patients enrolled in each…
There is more news in the androgenic alopecia space, as Eirion Therapeutics begins a Phase 1 trial for ET-02, a topical treatment. What is ET-02? According to Eirion Therapeutics, ET-02 works by targeting hair follicle stem cells that have become defective or inactive in individuals suffering from androgenic alopecia, enabling hair follicles to resume normal…
Correction (07/05/2024): Topadur Pharma has been in contact (read the comments below) and let us know that TOP-M119 does not contain sildenafil and nitroglycerin. We have corrected the reference to this in the article below. The information originated from a website called Il Messaggero, quote “The most curious thing is that the currently candidate drug,…
Kintor Pharmaceuticals has announced that its proteolysis targeting chimera (PROTAC) drug GT20029 has reached its primary endpoint in its Phase 2 trial in China. GT20029 is a topical PROTAC targeted toward AGA. What are PROTACs? PROTACs are a novel class of heterobifunctional molecules that can induce the degradation of target proteins by hijacking the cell’s…
Positive news to start the new year with Hope Medicine’s HMI-115 Phase 1b results announced on January 14th, 2024. Successful Results for Male Participants Hope Medicine has released positive data from their Phase 1b trial conducted in Australia titled, “An Open-Label Study, to Evaluate Safety, Tolerability, and Efficacy in Male and Female with Androgenetic Alopecia…